Ophthalmology

In this MD Newsline exclusive interview with vitreoretinal specialist Dr. Murtaza Adam, we discuss treatment strategies for wet AMD and the latest research. MD Newsline: What is your treatment strategy for wet AMD and how is it tailored to each patient? How do these treatments work? How do you decide when to switch treatments? Dr....

In this MD Newsline exclusive interview with vitreoretinal specialist Dr. Murtaza Adam, we discuss barriers to treatment adherence and COVID-19 as they relate to wet AMD. MD Newsline: What are the major barriers to wet AMD treatment adherence? Dr. Murtaza Adam: “The first thing people think about when they go for their first appointment for...

In this MD Newsline exclusive interview with vitreoretinal specialist Dr. Murtaza Adam, we discuss what wet age-related macular degeneration is and why it matters. MD Newsline: Can you explain why age-related macular degeneration (AMD) in general, and wet AMD in particular, are such important health issues? Dr. Murtaza Adam: “Age-related macular degeneration (AMD) is the...

In this MD Newsline exclusive interview with vitreoretinal specialist Dr. Murtaza Adam, we discuss risk factors for wet AMD. MD Newsline: Is there a genetic predisposition for wet AMD? Dr. Murtaza Adam: “Really, we don’t fully understand the genetic causes of age-related macular degeneration (AMD). We have implicated at least 70 genes in the development...

In this MD Newsline exclusive interview with vitreoretinal specialist Dr. Murtaza Adam, we discuss how to provide culturally sensitive care and overcome language barriers. MD Newsline: How have you been able to implement culturally sensitive care in your practice? Dr. Murtaza Adam: “Cultural sensitivity was a large component of my medical education. It wasn’t taught...

Razumab is the world’s first biosimilar ranibizumab. It has been approved for treating various types of macular disorders, including wet age-related macular degeneration (AMD). This prospective, multi-center, post-marketing study focuses on the safety and efficacy of biosimilar ranibizumab for patients with wet AMD. The 24-week study enrolled 126 patients with wet AMD. They were all...

The costs of treating wet age-related macular degeneration (AMD) are often very high, both at the individual and societal levels. This study focused on conducting a cost-benefit analysis of wet AMD treatment to understand the economic impact of these treatments. The study specifically compares three types of treatments: intravitreal bevacizumab, ranibizumab, and aflibercept. The study...

Several factors can increase the risk of developing age-related macular degeneration (AMD). This study focused on analyzing the association among IL-8 gene polymorphisms, IL-8 levels, and the risk of developing AMD. The study was conducted as a meta-analysis that relied on IL-8 -251A/T (rs4073) and +781C/T (rs2227306) polymorphisms and IL-8 levels in patients with AMD and...

This study focused on rates of hematologic inflammation in patients with age-related macular degeneration (AMD). Patients with wet AMD and dry AMD were included. The goal of the study was to find correlation patterns between hematologic inflammation and AMD, which could be useful for diagnostic and therapeutic purposes. This study analyzed data from 60 patients...